Skip to content

Arvinas ARVN Net margin

Net margin at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-411.4%+52.7pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-612%+602pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-302.6%
Immunome logo
ImmunomeIMNM
-5,593.8%-11,284pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-10,773.5%-878,492pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-156.4%-47.5pp

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's net margin?
Arvinas (ARVN) reported net margin of -247.5% in Q1 2026.
How has Arvinas's net margin changed year-over-year?
Arvinas's net margin decreased by 2167.7% year-over-year, from -10.9% to -247.5%.
What is the long-term trend for Arvinas's net margin?
Over 4 years (2020 to 2025), Arvinas's net margin has grown at a -49.2% compound annual growth rate (CAGR), from -460.6% to -30.8%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.